Drug Safety Matters

#5 Restoring invisible and abandoned trials – Peter Doshi

September 30, 2020 Uppsala Monitoring Centre
Drug Safety Matters
#5 Restoring invisible and abandoned trials – Peter Doshi
Chapters
Drug Safety Matters
#5 Restoring invisible and abandoned trials – Peter Doshi
Sep 30, 2020
Uppsala Monitoring Centre

Clinical trials are the “gold standard” of evidence-based medicine – the best way we have to test whether a drug is safe and effective before it enters the market. But if trial data is poorly reported or – even worse – left unpublished, how are we supposed to determine the true value of a medical treatment? Peter Doshi from the RIAT Support Center has made it his mission to fix the problem and improve data transparency for good.

Tune in to find out:

  • How publication and reporting biases affect our understanding of trial results
  • How an investigation into anti-influenza drugs helped galvanise a general movement towards greater data transparency 
  • How the RIAT Support Center is facilitating the correction of the scientific record

Want to know more?

The Restoring Invisible & Abandoned Trials (RIAT) Support Center offers free support to researchers anywhere in the world that would like to publish an unpublished trial or correct a misreported trial.

The AllTrials campaign calls for all past and present clinical trials to be registered and their results reported.

The Tamiflu campaign highlighted important discrepancies between journal publications and the underlying clinical study reports, and increased awareness of the importance of independent access to underlying trial data.

A 2016 systematic review found that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study. 

Authors from the European Medicines Agency debate whether clinical trial publications are a sufficient basis for healthcare decisions.

Peter Doshi and David Healy argue that doctors should not recommend COVID-19 treatments and vaccines when full data are not publicly available.

Join the conversation on social media
Follow us on Twitter, Facebook or LinkedIn and share your thoughts about the show with the hashtag #DrugSafetyMatters.

Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!

About UMC
Read more about Uppsala Monitoring Centre and how we work to make medicines safer for patients.

Show Notes

Clinical trials are the “gold standard” of evidence-based medicine – the best way we have to test whether a drug is safe and effective before it enters the market. But if trial data is poorly reported or – even worse – left unpublished, how are we supposed to determine the true value of a medical treatment? Peter Doshi from the RIAT Support Center has made it his mission to fix the problem and improve data transparency for good.

Tune in to find out:

  • How publication and reporting biases affect our understanding of trial results
  • How an investigation into anti-influenza drugs helped galvanise a general movement towards greater data transparency 
  • How the RIAT Support Center is facilitating the correction of the scientific record

Want to know more?

The Restoring Invisible & Abandoned Trials (RIAT) Support Center offers free support to researchers anywhere in the world that would like to publish an unpublished trial or correct a misreported trial.

The AllTrials campaign calls for all past and present clinical trials to be registered and their results reported.

The Tamiflu campaign highlighted important discrepancies between journal publications and the underlying clinical study reports, and increased awareness of the importance of independent access to underlying trial data.

A 2016 systematic review found that much of the information on adverse events remains unpublished and that the number and range of adverse events is higher in unpublished than in published versions of the same study. 

Authors from the European Medicines Agency debate whether clinical trial publications are a sufficient basis for healthcare decisions.

Peter Doshi and David Healy argue that doctors should not recommend COVID-19 treatments and vaccines when full data are not publicly available.

Join the conversation on social media
Follow us on Twitter, Facebook or LinkedIn and share your thoughts about the show with the hashtag #DrugSafetyMatters.

Got a story to share?
We’re always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!

About UMC
Read more about Uppsala Monitoring Centre and how we work to make medicines safer for patients.